Suppr超能文献

肿瘤坏死因子相关凋亡诱导配体(TRAIL)可诱导具有间充质表型的三阴性乳腺癌细胞发生凋亡。

TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype.

作者信息

Rahman Monzur, Davis Sean R, Pumphrey Janet G, Bao Jing, Nau Marion M, Meltzer Paul S, Lipkowitz Stanley

机构信息

Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Blg 37, Room 2066, 37 Convent Drive, Bethesda, MD 20892-4256, USA.

出版信息

Breast Cancer Res Treat. 2009 Jan;113(2):217-30. doi: 10.1007/s10549-008-9924-5. Epub 2008 Feb 12.

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in some but not all breast cancer cell lines. Breast cancers can be divided into those which express the estrogen (ER) and progesterone (PR) receptors, those with HER-2 amplification, and those without expression of ER, PR, or HER-2 amplification (referred to as basal or triple-negative breast cancer). We tested a panel of 20 breast cancer cell lines representing the different types of breast cancer to evaluate if the molecular phenotype of the breast cancer cells determined their response to TRAIL. The most striking finding was that eight of eleven triple-negative cell lines are sensitive to TRAIL-mediated apoptosis. The eight TRAIL-sensitive triple-negative cell lines have a mesenchymal phenotype while the three TRAIL-resistant triple-negative cell lines have an epithelial phenotype. Two of five cell lines with HER-2 amplification were sensitive to TRAIL and none of the five ER positive cell lines were sensitive. RNAi-mediated knockdown of TRAIL receptor expression demonstrated that TRAIL Receptor 2 (TRAIL-R2) mediates the effects of TRAIL, even when both TRAIL-R1 and TRAIL-R2 are expressed. Finally, inhibition of EGFR, expressed in both TRAIL-sensitive and TRAIL-resistant triple-negative breast cancer cell lines, using a small molecule tyrosine kinase inhibitor (AG1478), enhanced TRAIL-induced apoptosis in TRAIL-sensitive cell lines but did not convert resistant cells into TRAIL-sensitive cells. Together, these findings suggest that a subset of triple-negative breast cancer, those with mesenchymal features, may be the most likely to benefit from TRAIL targeted therapy. These findings could form the basis to select breast cancer patients for clinical trials of TRAIL-R2 ligands.

摘要

肿瘤坏死因子相关凋亡诱导配体(TRAIL)可诱导部分而非全部乳腺癌细胞系发生凋亡。乳腺癌可分为表达雌激素(ER)和孕激素(PR)受体的类型、HER-2基因扩增的类型以及不表达ER、PR或HER-2基因扩增的类型(称为基底样或三阴性乳腺癌)。我们检测了一组代表不同类型乳腺癌的20种乳腺癌细胞系,以评估乳腺癌细胞的分子表型是否决定其对TRAIL的反应。最显著的发现是,11种三阴性细胞系中有8种对TRAIL介导的凋亡敏感。8种对TRAIL敏感的三阴性细胞系具有间充质表型,而3种对TRAIL耐药的三阴性细胞系具有上皮表型。5种HER-2基因扩增的细胞系中有2种对TRAIL敏感,而5种ER阳性细胞系均不敏感。RNA干扰介导降低TRAIL受体表达表明,即使TRAIL-R1和TRAIL-R2均表达,TRAIL受体2(TRAIL-R2)也介导TRAIL的作用。最后,使用小分子酪氨酸激酶抑制剂(AG1478)抑制TRAIL敏感和TRAIL耐药的三阴性乳腺癌细胞系中均表达的表皮生长因子受体(EGFR),可增强TRAIL敏感细胞系中TRAIL诱导的凋亡,但不能将耐药细胞转化为对TRAIL敏感的细胞。总之,这些发现表明,具有间充质特征的三阴性乳腺癌亚群可能最有可能从TRAIL靶向治疗中获益。这些发现可为选择乳腺癌患者进行TRAIL-R2配体的临床试验奠定基础。

相似文献

1
TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype.
Breast Cancer Res Treat. 2009 Jan;113(2):217-30. doi: 10.1007/s10549-008-9924-5. Epub 2008 Feb 12.
3
Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer.
Clin Cancer Res. 2011 Aug 1;17(15):5005-15. doi: 10.1158/1078-0432.CCR-11-0099. Epub 2011 Jun 8.
4
The TRAIL to targeted therapy of breast cancer.
Adv Cancer Res. 2009;103:43-73. doi: 10.1016/S0065-230X(09)03003-6.
6
WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis.
Mol Cancer Res. 2012 Jan;10(1):75-85. doi: 10.1158/1541-7786.MCR-11-0500. Epub 2011 Nov 23.
7
Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome.
Breast Cancer Res Treat. 2010 Jul;122(2):347-57. doi: 10.1007/s10549-009-0571-2. Epub 2009 Oct 10.
8
Enhanced anticancer effect of the combination of cisplatin and TRAIL in triple-negative breast tumor cells.
Mol Cancer Ther. 2011 Mar;10(3):550-7. doi: 10.1158/1535-7163.MCT-10-0571. Epub 2011 Jan 20.
9
TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):716-23. doi: 10.1016/j.ijrobp.2007.03.057. Epub 2007 May 18.

引用本文的文献

2
Enhancer regulatory networks globally connect non-coding breast cancer loci to cancer genes.
Genome Biol. 2025 Jan 17;26(1):10. doi: 10.1186/s13059-025-03474-0.
3
Nanoparticle-mediated gene delivery of TRAIL to resistant cancer cells: A review.
Heliyon. 2024 Aug 8;10(16):e36057. doi: 10.1016/j.heliyon.2024.e36057. eCollection 2024 Aug 30.
5
WWP1 E3 ligase at the crossroads of health and disease.
Cell Death Dis. 2023 Dec 21;14(12):853. doi: 10.1038/s41419-023-06380-0.
6
Synergistic antitumor effects of circularly permuted TRAIL with doxorubicin in triple-negative breast cancer.
Acta Biochim Biophys Sin (Shanghai). 2023 Aug 10;55(8):1247-1256. doi: 10.3724/abbs.2023160.
7
CDH1 overexpression sensitizes TRAIL resistant breast cancer cells towards rhTRAIL induced apoptosis.
Mol Biol Rep. 2023 Sep;50(9):7283-7294. doi: 10.1007/s11033-023-08657-1. Epub 2023 Jul 8.
8
The autophagic protein FYCO1 controls TNFRSF10/TRAIL receptor induced apoptosis and is inactivated by CASP8 (caspase 8).
Autophagy. 2023 Oct;19(10):2733-2751. doi: 10.1080/15548627.2023.2229656. Epub 2023 Jul 7.
10
Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer.
Cancers (Basel). 2023 Mar 23;15(7):1936. doi: 10.3390/cancers15071936.

本文引用的文献

1
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.
Nat Med. 2007 Sep;13(9):1070-7. doi: 10.1038/nm1627. Epub 2007 Sep 2.
2
Moesin expression is a marker of basal breast carcinomas.
Int J Cancer. 2007 Oct 15;121(8):1779-85. doi: 10.1002/ijc.22923.
3
Molecular definition of breast tumor heterogeneity.
Cancer Cell. 2007 Mar;11(3):259-73. doi: 10.1016/j.ccr.2007.01.013.
5
Understanding ERM proteins--the awesome power of genetics finally brought to bear.
Curr Opin Cell Biol. 2007 Feb;19(1):51-6. doi: 10.1016/j.ceb.2006.12.004. Epub 2006 Dec 18.
6
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell. 2006 Dec;10(6):515-27. doi: 10.1016/j.ccr.2006.10.008.
7
Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.
Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8634-9. doi: 10.1073/pnas.0510187103. Epub 2006 May 26.
8
TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.
Cancer Res. 2005 Dec 15;65(24):11265-70. doi: 10.1158/0008-5472.CAN-05-2801.
9
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
Mod Pathol. 2006 Feb;19(2):264-71. doi: 10.1038/modpathol.3800528.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验